The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

MARCH 3, 2025

a clinic) or at home. We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives, says Cristina Has, MD, Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany, in a news release.

Therapy 36

Therapy Clinic Hospital Dermatology 36

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy. Platelet-Rich Plasma Therapy for Hair Growth: A Systematic Review. Dermatology Clinics. Clinical and Aesthetic Dermatology.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

Dermatology Times

OCTOBER 3, 2024

Brad Glick, DO, MPH, discusses how to effectively introduce photodynamic therapy (PDT) into a dermatology clinic by outlining necessary equipment and setup, providing guidance on essential patient discussions for treatment introduction, and sharing strategies to ensure treatment efficacy while prioritizing patient safety and satisfaction.

Clinic 36

Clinic Therapy Safety Dermatology 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Whether caused by sun exposure, hormonal fluctuations, post-inflammatory responses, or genetic factors, pigmentation can present unique challenges in clinical practice. In 2016, Krystal completed her clinical doctorate in nursing practice. Tranexamic Acid in Dermatology: Current Perspectives and Clinical Outcomes. Farris, P.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

MARCH 9, 2025

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4%

Dermatitis 36

Dermatitis Safety Office Eczema 36

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Training Clinic 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Training Clinic 78

The Dermatology Digest

FEBRUARY 18, 2025

This approval is based on robust results from the Phase III ARCADIA and OLYMPIA clinical trial programs, which demonstrated that nemolizumab clinically improved skin lesions, itch, and sleep disturbance in atopic dermatitis and prurigo nodularis, respectively.

Dermatitis 36

Dermatitis Hospital Marketing Clinic 36

The Dermatology Digest

FEBRUARY 11, 2025

is restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA). “We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. Q32 Bio Inc.

Clinic 36

Clinic Therapy Office Tools 36

US Dermatologt Partners

JUNE 1, 2024

In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. 2 Newer Generation Oral Therapies “We live in an exciting time because we’ve got new topical therapies, multiple oral therapies, and obviously, an array of biologic agents and patient preferences change,” Lockshin said.

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.

Treatments 77

Treatments Dermatitis Therapy Medical 77

New Age Spa Institute

NOVEMBER 20, 2024

Certifications are typically focused on specific skills, such as makeup artistry, clinical aesthetics, or advanced techniques in skincare. Licenses like those for esthetics, cosmetology , and massage therapy give professionals the legal right to practice their craft and offer services to the public. Don’t forget!

Esthetics 52

Esthetics Therapy Continuing Education Continuous Education 52

The Dermatology Digest

NOVEMBER 6, 2024

Providing up to $450,000 over two years, the TBA emerged as a key initiative of LRA’s newly developed Research Roadmap , a research strategy designed to integrate LRA’s efforts across all stages of lupus research, from early discovery through clinical application.

Hospital 36

Hospital Therapy Networking Management 36

The Dermatology Digest

MARCH 5, 2025

Unlike traditional acne therapies, XYNGARI is designed as a once-weekly, natural, topical treatment with multiple mechanisms of action that target the root causes of acne. The XYNGARI Phase 3 STAR-1 clinical study will evaluate the efficacy, safety, and tolerability of Xyngari in patients with moderate-to-severe facial acne.

Treatments 36

Treatments Rosacea Pores Office 36

The Dermatology Digest

JANUARY 13, 2025

Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Robin, President and CEO of Nektar Therapeutics, in a news release.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

FEBRUARY 11, 2024

A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE). This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer.

Dermatology 74

Dermatology Safety Clinic Therapy 74

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

FEBRUARY 8, 2024

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Dermatology Times

DECEMBER 5, 2024

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.

Safety 36

Safety Therapy Clinic 36

Aesthetics Advisor

AUGUST 18, 2023

Key Points: A few studies show that NAD+ IV therapy can alleviate alcohol and drug addiction, as well as Parkinson’s disease, but no studies have examined its effects on aging. Oral administration of NAD+ boosting therapy is safer, more cost effective, and more consistently dosed than intravenous administartion.

Therapy 36

Therapy Injections Safety Clinic 36

The Dermatology Digest

APRIL 4, 2024

The sBLA in moderate-to-severe HS is supported by data from the Phase 3 BE HEARD I and BE HEARD II studies where Bimzelx demonstrated clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response-50 (HiSCR50) vs. placebo at Week 16, the primary endpoint. Bimzelx was approved in the U.S. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Innovations Safety 36

The Dermatology Digest

MAY 22, 2024

The first patient has been dosed in Zai Lab’s global Phase 2 clinical trial of ZL-1102, a topical anti-IL-17 investigational therapy for the treatment of mild to moderate chronic plaque psoriasis. In this 5-arm trial, approximately 250 patients will receive topical therapy for 16 weeks.

Clinic 36

Clinic Therapy Safety Treatments 36

The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s

Office 74

Office Clinic Safety Medical 74

Aesthetics Advisor

JULY 4, 2024

In recent years, the allure of IV drip therapy has surged, captivating both health enthusiasts and celebrities alike. In an exploration of the scientific realms of IV drip therapy, we talked to Dr. Anant Vinjamoori, MD, Chief Medical Officer of Modern Age and Harvard-trained longevity expert. What is IV drip therapy?

Therapy 36

Therapy Vitamin C Injections Medical 36

The Dermatology Digest

MARCH 12, 2024

in patients with HS met its primary endpoint, reinforcing the efficacy and safety profile of ruxolitinib cream 1.5%, demonstrating potential as a novel treatment option for people living with HS,” study author Martina J. The Phase 2 study evaluating ruxolitinib cream, 1.5% achieved a 75% reduction (AN75), 20.8%

Therapy 69

Therapy Dermatology Safety Treatments 69

US Dermatologt Partners

JANUARY 13, 2025

Professional acne extractions are clinical procedures where blackheads, whiteheads, and other types of blemishes are removed, during a dermatologic appointment. What Are Acne Extractions? This can be done manually, utilizing tools, or in case of severe, inflammatory forms of acne, surgical extraction may be required.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

The Dermatology Digest

FEBRUARY 16, 2024

One of the biggest challenges in CAR T-cell therapies is the scarcity of suitable tumor targets,” says study author Cristina Puig-Saus, PhD, assistant professor of medicine at the David Geffen School of Medicine at UCLA, in a news release.

Therapy 36

Therapy Clinic Safety Treatments 36

New Age Spa Institute

SEPTEMBER 19, 2024

Let’s take a closer look at the safety concerns surrounding UV lashes: Light Strength Comparison: The LED light used in UV lash extensions is typically 5 watts, much less powerful than a nail lamp (50+ watts) or a tanning bed (1,500-2,000 watts). But I’m cautious about long-term safety, especially with UV exposure near the eyes.”

Lash Extensions 52

Lash Extensions Safety Irritation Makeup 52

Aesthetics Advisor

AUGUST 15, 2023

Curcumin may help increase healthy p53 levels, and it has been shown to be a potentially effective cancer therapy supplement. Since fenbendazole is a veterinary medicine, and is not licensed for human use and there is no specific human safety data available. Click here to buy Theracurmin HP by Integrative Therapeutics (Amazon) 3.

Therapy 69

Therapy Medical Safety Diet 69

Aesthetics Advisor

AUGUST 19, 2023

Nevertheless, PRP and exosome-related therapies are not yet established as standard treatments, given their relatively recent emergence. Because the human body is specially equipped to heal itself, and regenerative therapies tap into this powerful ability. Regenerative medicine is also becoming a buzzword in the medical community.

Therapy 36

Therapy Injections Medical Treatments 36

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications. and Novartis Pharmaceuticals).

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36